Chimerix Inc (CXF.BE)
| Previous close | 0.8420 |
| Open | 0.8700 |
| Bid | 0.7880 x 0 |
| Ask | 0.8780 x 0 |
| Day's range | 0.8310 - 0.8830 |
| 52-week range | 0.8198 - 1.4595 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule
Simply Wall St.We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Chimerix Appoints Marc D. Kozin to Board of Directors
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe
